close

Biocon targets $200 mn revenue from biosimilars on the back of EMs growth

The approval of Biocon's biosimilar insulin Glargine in about 25 countries will be a revenue-driving force

Employees of Biocon Ltd work inside the company's research and development centre in Bengaluru. File photo: Reuters
Premium

Employees of Biocon Ltd work inside the company's research and development centre in Bengaluru. File photo: Reuters

Bengaluru
Biotechnology major Biocon is aiming to register a 66 per cent growth in its biologics business this fiscal, which the company hopes will help it clock a revenue of $200

Also Read

Biocon: Monetisation of drug pipeline in emerging markets to boost earnings

USFDA approvals can unlock $1 bn biosimilar business for Biocon in the US

The obvious opportunity is biosimilars, says Biocon's Kiran Mazumdar-Shaw

Biosimilar progress adds to Biocon's prospects as stock gains 14%

Biocon dips 4% on seven USFDA observations for Bengaluru drug facility

Freshworks raises $100 million from Sequoia and Accel, hires new CFO

TPG signs pact to invest in South India-based Five Star Business Finance

CBI arrests Saket SHO in bribery case, books Unitech founder Ramesh Chandra

BEML keen on developing bullet train coaches in India, but awaits clarity

Daimler India MD & CEO steps down, to move to company HQ for new assignment

First Published: Aug 1 2018 | 5:30 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com